# Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)

> **NCT04296864** · PHASE2 · UNKNOWN · sponsor: **Andover Eye Associates** · enrollment: 42 (estimated)

## Conditions studied

- Atopic Keratoconjunctivitis

## Interventions

- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT04296864
- **Lead sponsor:** Andover Eye Associates
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-10
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04296864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04296864, "Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04296864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*